Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carina Heydt

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Scientific Reports|July 11, 2020
Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencingCarina Heydt, Jan Rehker, Roberto Pappesch, et al.
Plos One|August 9, 2014
Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnosticsCarina Heydt, Jana Fassunke, Helen Künstlinger, et al.
The Journal of Molecular Diagnostics : JMD|July 22, 2017
Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation TestingChristina Alidousty, Danielle Brandes, Carina Heydt, et al.
Molecular Oncology|April 23, 2015
miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumoursMichaela Angelika Ihle, Marcel Trautmann, Helen Kuenstlinger, et al.
BMC Cancer|April 18, 2015
Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapyCarina Heydt, Niklas Kumm, Jana Fassunke, et al.
Plos One|April 7, 2015
MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomasKatja Schmitz, Hartmut Koeppen, Elke Binot, et al.
BMC Cancer|May 14, 2020
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsSvenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, et al.
The Journal of Molecular Diagnostics : JMD|August 6, 2019
Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid TumorsCarina Heydt, Vanessa Ruesseler, Roberto Pappesch, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2018
Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogiesRoberta Castiglione, Christina Alidousty, Barbara Holz, et al.
BMC Gastroenterology|February 6, 2019
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinomaAlexander Quaas, Carina Heydt, Dirk Waldschmidt, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Scientific Reports|July 11, 2020
Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencingCarina Heydt, Jan Rehker, Roberto Pappesch, et al.
Plos One|August 9, 2014
Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnosticsCarina Heydt, Jana Fassunke, Helen Künstlinger, et al.
The Journal of Molecular Diagnostics : JMD|July 22, 2017
Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation TestingChristina Alidousty, Danielle Brandes, Carina Heydt, et al.
Molecular Oncology|April 23, 2015
miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumoursMichaela Angelika Ihle, Marcel Trautmann, Helen Kuenstlinger, et al.
BMC Cancer|April 18, 2015
Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapyCarina Heydt, Niklas Kumm, Jana Fassunke, et al.
Plos One|April 7, 2015
MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomasKatja Schmitz, Hartmut Koeppen, Elke Binot, et al.
BMC Cancer|May 14, 2020
Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsSvenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, et al.
The Journal of Molecular Diagnostics : JMD|August 6, 2019
Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid TumorsCarina Heydt, Vanessa Ruesseler, Roberto Pappesch, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2018
Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogiesRoberta Castiglione, Christina Alidousty, Barbara Holz, et al.
BMC Gastroenterology|February 6, 2019
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinomaAlexander Quaas, Carina Heydt, Dirk Waldschmidt, et al.
Pageof 6